Albizia chinensis bark extract ameliorates the genotoxic effect of cyclophosphamide

Bulletin of the National Research Centre

Table 1 Frequency of chromosomal abnormalities in mouse bone marrow induced after treatment with CP and MEAC

Treatments and doses (mg/kg)	Total abnormal metaphases			No. of different types of abnormal metaphases						Inhibitory index excluding gaps
	No.	Mean(%) ± SE		G.	Frag. and/or Br.	Del.	C.F.	M.A.	Polyp.
	No.	Including gaps	Excluding gaps	G.	Frag. and/or Br.	Del.	C.F.	M.A.	Polyp.
I. Control	23	4.60 ± 0.58	2.60 ± 0.48^a	10	9	4	0	0	0	–
II.CP (20)	119	23.80 ± 0.52^a	19.20 ± 0.60^d	23	43	10	6	32	5	–
III. MEAC (100)	23	4.60 ± 0.50	2.40 ± 0.62^a	11	8	4	0	0	0	–
IV. MEAC (25 × 7 days)	25	5.00 ± 0.58	3.00 ± 0.52^a	10	12	3	0	0	0	–
Single dose
V. MEAC (25) + CP	113	22.60 ± 0.54^a	18.20 ± 0.50^d	22	52	9	4	21	5	7
VI. MEAC (50) + CP	107	21.40 ± 0.70^a	16.80 ± 0.65^d	23	50	6	3	23	2	15
VII. MEAC(100) + CP	91	18.20 ± 0.65^ab	14.00 ± 0.55^bc	21	45	7	1	15	2	32
Repeated dose
VIII. MEAC (25 × 3 days) + CP	105	21.00 ± 0.58^a	16.60 ± 0.70^d	22	49	9	2	20	3	16
IX. MEAC (25 × 7 days) + CP	85	17.00 ± 0.56^ab	13.00 ± 0.65^bc	20	42	5	1	16	1	38

Total number of examined metaphases 500 (100 metaphases/animal, 5 animals/group)
The values having different superscript letters in each column are significantly different from one another as calculated by ANOVA
G. gap, Frag. fragment, Br. breaks, Del. deletions, C.F. centric fusions, M.A. multiple aberrations, Polyp polyploidy